Immediate Impact
1 from Science/Nature 49 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
The interaction of innate immune and adaptive immune system
2024 Standout
Works of Danielle M. Brander being referenced
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
2021
Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Danielle M. Brander | 679 | 528 | 203 | 216 | 85 | 892 | |
| Herbert Eradat | 542 | 509 | 262 | 250 | 59 | 925 | |
| John N. Allan | 745 | 674 | 304 | 197 | 93 | 1.1k | |
| Georg Aue | 606 | 433 | 351 | 238 | 52 | 1.0k | |
| Lukáš Smolej | 559 | 515 | 280 | 124 | 75 | 858 | |
| Anna‐Maria Fink | 858 | 800 | 358 | 101 | 57 | 1.0k | |
| Wataru Munakata | 326 | 628 | 164 | 192 | 99 | 1.1k | |
| Jerzy Z. Błoński | 770 | 625 | 393 | 218 | 72 | 1.2k | |
| Martin Šimkovič | 906 | 763 | 326 | 101 | 54 | 1.0k | |
| Romain Guièze | 372 | 246 | 187 | 203 | 61 | 838 | |
| Marie‐Christine Kyrtsonis | 473 | 409 | 174 | 358 | 79 | 1.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...